| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/18/2005 | US20050180975 Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma |
| 08/18/2005 | US20050180973 TREM-1 splice variant for use in modifying immune responses |
| 08/18/2005 | US20050180968 RLX is able to modulate the biological activity of bone marrow-derived cells, such as mast cells, platelets and granulocytes, and to reduce the allergic asthma-like reaction elicited by antigen inhalation |
| 08/18/2005 | US20050180966 administering Product R, a peptide-nucleic acid preparation; rheumatoid arthritis; further comprising prednisone, methotrexate, cyclophosphamide, imuran or cyclosporin A |
| 08/18/2005 | US20050180965 Heat-reversible composition treating hyposalia and asialia |
| 08/18/2005 | US20050180964 Methods and compositions for the inhibition of growth of infectious Aspergillus fumigatus and other mycotic organisms in the gut of mammalian and avian species |
| 08/18/2005 | US20050180960 producer cell (encapsulated in a matrix containing immunostimulating alginates) expresses a molecule that is an inhibitor of the growth of a CNS tumor |
| 08/18/2005 | US20050180959 Kinases involved in the regulation of energy homeostasis |
| 08/18/2005 | US20050180957 composition comprising a fibrinogen, a fibrinolysis inhibitor, an angiogenic growth factor, one or more encapsulated cells, a thrombin and a divalent salt; stimulating vascularization at a transplant site |
| 08/18/2005 | US20050180955 gene therapy; delivering recombinant adeno-associated virus virions to the brain; pumping; transgene encodes an aromatic amino acid decarboxylase |
| 08/18/2005 | US20050180954 Drug for treating bone disorders |
| 08/18/2005 | US20050180953 peptides derivatives as an agent inducing cells differentiation and in particular, to their use in antitumor noncytotoxic therapy; melanoma; most preferred compound used in the present invention is 4-[N-(2-imidazol-4-yl)ethyl)carbamoyl]butyric acid (Dicarbamine (reg) ) |
| 08/18/2005 | US20050180952 agent has a higher tissue bioavailability in a particular tissue; benefits and improvements over conventional drug delivery methods including dose sparing, increased drug efficacy, reduced side effects, reduced metastatic potential and prolonged survival |
| 08/18/2005 | US20050180951 Fusion of autologous dendrtic cells with cancer cells that have the same class I MHC haplotype as said patient; and interleukin-12 |
| 08/18/2005 | US20050180950 Chemically modified TNF-alpha |
| 08/18/2005 | US20050180948 Protein based TNF-alpha variants for the treatment of TNF-alpha related disorders |
| 08/18/2005 | US20050180947 Novel application of vaccination against TNF-alpha |
| 08/18/2005 | US20050180946 such as triethanolamine with 2 hydroxyethyl groups derivatized with polyethylene glycol, and the amine group conjugated to drugs such as antitumor agent interferon |
| 08/18/2005 | US20050180928 peptide having a specific amino acid sequence suppresses initial adhesion of intraoral bacteria to teeth and periodontal tissue and prevents formation of a biofilm in an oral cavity. |
| 08/18/2005 | US20050178396 Polymer compositions and methods for their use |
| 08/18/2005 | US20050178395 Polymer compositions and methods for their use |
| 08/18/2005 | DE102004022746A1 Side-effect free thrombolytic tablets for combating disposition towards thromboembolism, containing acetylsalicylic acid and dry extracts of melilot, horse chestnut seed and butcher's broom root |
| 08/18/2005 | DE102004004509A1 Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden Use of low-dose erythropoietin for stimulation of endothelial progenitor cells and the organ regeneration and slowing progression of organ damage |
| 08/18/2005 | CA2847517A1 Use of alkaline phosphatase for the detoxification of lps present at mucosal barriers |
| 08/18/2005 | CA2560055A1 Method of inducing or modulating immune response |
| 08/18/2005 | CA2558733A1 A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual |
| 08/18/2005 | CA2556161A1 Heparan-sulfate proteoglycan degrading enzymes for promotion of nerve regeneration |
| 08/18/2005 | CA2556152A1 Peptide mixtures with immunomodulatory activity |
| 08/18/2005 | CA2555684A1 Crystal structures and models for fc receptors and uses thereof in the design or identification of fc receptor modulator compounds |
| 08/18/2005 | CA2555469A1 Use of relaxin-3 for promoting food intake, increasing body weight gain, increasing fat weight and for others |
| 08/18/2005 | CA2555463A1 Inhibitors of tgf-r signaling for treatment of cns disorders |
| 08/18/2005 | CA2555199A1 Peptidylarginine deiminase 4 inhibitor |
| 08/18/2005 | CA2555083A1 Genes associated with canine osteoarthritis and related methods and compositions |
| 08/18/2005 | CA2555025A1 Use of factor viia factor for treating trauma |
| 08/18/2005 | CA2555024A1 Use of factor viia for treating late complications of trauma |
| 08/18/2005 | CA2555018A1 Treatment of conditions involving dopaminergic neuronal degeneration using nogo receptor antagonists |
| 08/18/2005 | CA2554880A1 Methods and compositions for modulating angiogenesis |
| 08/18/2005 | CA2554809A1 Novel n-alkyl thiourea-and thioamide-substituted imidazolyl inhibitors and glutaminyl cyclase |
| 08/18/2005 | CA2554779A1 Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
| 08/18/2005 | CA2554761A1 Neuroprotective dietary supplement |
| 08/18/2005 | CA2554683A1 Use of alkaline phosphatase for the detoxification of lps present at mucosal barriers |
| 08/18/2005 | CA2554634A1 Compositions, methods and uses for a novel family of peptides |
| 08/18/2005 | CA2554632A1 Method of treating hemolytic disease |
| 08/18/2005 | CA2554628A1 Methods of modulating cd200 and cd200r |
| 08/18/2005 | CA2554526A1 Variants of the extracellular domain of bcma and uses thereof |
| 08/18/2005 | CA2554353A1 Treatment of neurodegenerative diseases by the use of gpr49 |
| 08/18/2005 | CA2554352A1 Compositions containing internally activated antioxidant |
| 08/18/2005 | CA2554262A1 Sustained-release preparations |
| 08/18/2005 | CA2553040A1 Modified human four helical bundle polypeptides and their uses |
| 08/18/2005 | CA2553035A1 Modified human growth hormone polypeptides and their uses |
| 08/18/2005 | CA2553034A1 Modified human interferon polypeptides and their uses |
| 08/18/2005 | CA2552955A1 Induction of apoptosis via arts-iap complexes |
| 08/18/2005 | CA2552404A1 Methods and compositions for the treatment of lipodystrophy |
| 08/18/2005 | CA2552285A1 Sulfhydryl protected glythathione prodrug |
| 08/18/2005 | CA2547843A1 Composition comprising polymeric material and uses thereof |
| 08/17/2005 | EP1564292A1 Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides |
| 08/17/2005 | EP1564286A1 Hybrid proteins of beta-lactamase class A |
| 08/17/2005 | EP1564219A1 N-terminally monopegylated polypeptides and process for their preparation |
| 08/17/2005 | EP1564218A1 Composition for oral cavity |
| 08/17/2005 | EP1563847A1 Agent eleveting dendritic cell precursor level in blood |
| 08/17/2005 | EP1563844A2 Wound healing formulations containing human plasma fibronectin |
| 08/17/2005 | EP1563843A1 Botulinum toxins for treating various disorders and associated pain |
| 08/17/2005 | EP1563834A1 Hollow nanoparticles of protein and drug using the same |
| 08/17/2005 | EP1563309A2 Use of nuclear hormone receptors to identify meiosis regulating compounds |
| 08/17/2005 | EP1563308A2 Methods and kits for diagnosing tumorigenicity |
| 08/17/2005 | EP1563300A2 Diagnostic method for celiac sprue |
| 08/17/2005 | EP1563080A1 Method for expressing inducible rnai in cells, nucleic acid molecules therefor and cells transformed by said molecules |
| 08/17/2005 | EP1563071A2 Protein specific to pancreatic beta cells in islets of langerhans and applications thereof |
| 08/17/2005 | EP1563063A2 Calmodulin independent activation of nitric oxide synthase by nadph analogs |
| 08/17/2005 | EP1563056A2 Composition and method for treating lupus nephritis |
| 08/17/2005 | EP1562986A2 Compounds and methods for modulating functions of classical cadherins |
| 08/17/2005 | EP1562985A2 Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases |
| 08/17/2005 | EP1562981A2 Ligands |
| 08/17/2005 | EP1562980A2 Nuclear factor of activated t cells receptor |
| 08/17/2005 | EP1562979A2 Tubulysins, method for producing the same and tubulysin preparations |
| 08/17/2005 | EP1562977A2 Active specific immunotherapy of cancer metastasis |
| 08/17/2005 | EP1562970A2 COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF HIF-1 ALPHA |
| 08/17/2005 | EP1562969A2 Novel human cell surface protein with immunoglobulin folds, bgs-19 |
| 08/17/2005 | EP1562967A2 Adipocyte complement related protein zacrp14 |
| 08/17/2005 | EP1562652A1 Collagen-based materials and methods for treating synovial joints |
| 08/17/2005 | EP1562634A1 Positional isomers of peg ifn alpha 2a |
| 08/17/2005 | EP1562632A2 Inducible ligand for alpha1 beta1 integrin and uses |
| 08/17/2005 | EP1562631A1 Bowman-birk inhibitor concentrate product and process |
| 08/17/2005 | EP1562630A2 Injectible bioadhesive polymeric hydrogels as well as related methods of enzymatic preparation |
| 08/17/2005 | EP1562629A1 Therapeutic uses of beta-casein a2 and dietary supplement containing beta-casein a2 |
| 08/17/2005 | EP1562628A1 Dc-sign blockers and their use for preventing or treating viral infections. |
| 08/17/2005 | EP1562625A2 Pain relief agents |
| 08/17/2005 | EP1562624A2 Orally administered peptides synergize statin activity |
| 08/17/2005 | EP1562623A1 Method of treating or preventing obeisity and lipid metabolism disorders and compositions for use therein |
| 08/17/2005 | EP1562622A2 Immunogenic epitopes for fibroblast growth factor 5 (fgf-5) presented by hla-a3 and hla-a2 |
| 08/17/2005 | EP1562621A1 Composition and method for treating inflammatory diseases using protease inhibitors |
| 08/17/2005 | EP1562620A2 Modified cytokines for use in cancer therapy |
| 08/17/2005 | EP1562605A2 Compounds for modulation of cholesterol transport |
| 08/17/2005 | EP1562597A2 Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| 08/17/2005 | EP1562592A2 Histone deacetylase inhibitors for treating degenerative diseases of the eye |
| 08/17/2005 | EP1562587A2 Novel compositions and methods for the treatment of immune related diseases |
| 08/17/2005 | EP1562577A1 Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropathies induced by anticancer agents |
| 08/17/2005 | EP1562564A2 Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy |
| 08/17/2005 | EP1562561A1 Stable aerosol formulation of peptides and proteins with non-cfc propellants |
| 08/17/2005 | EP1562422A2 Compositions and methods for prolonging survival of platelets |